At a glance
ClinicalIndex Comparison RecordN/ACompleted· 387 enrolled
Drug / intervention
PET/CT and EBV DNAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Combining Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography and Plasma EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced Nasopharyngeal Carcinoma
In Brief
An observational study evaluating PET/CT and EBV DNA for Nasopharyngeal Carcinoma. Completed, enrolled 387 participants across 1 site.
Detailed Summary
PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of progression in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartOct 2018
Primary CompletionDec 2019
Study CompletionDec 2020
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartOct 1, 2018
Primary CompletionDec 12, 2019
Study CompletionDec 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.9 years ago
Interventions
PET/CT and EBV DNAdevice
PET/CT and EBV DNA will be proformed after the IMRT treatment